Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevoflurane vs Propofol for sedation in sepsis-related ARDS
NCT04014218Phase 4Unknown
- Sponsor
- MONIKI
- Start
- Jan 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sevoflurane in acute respiratory distress syndrome (ARDS) (2 arms), sponsored by MONIKI. Primary endpoints: Mortality at 28 days, ICU Length of Stay at 45 days and 1 more. Status: unknown.
02
Drugs
sevoflurane
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04014218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04014218.